alexa Lupus nephritis | India| PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Conferences
  • 22nd European Nephrology Conference
    October 15-16, 2018 Warsaw, Poland
  • 18th International Conference on Nephrology & Therapeutics
    October 22-23, 2018 Osaka, Japan

Relevant Topics

Lupus Nephritis

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Lupus nephritis

    Lupus nephritis is inflammation of the kidney that is caused by systemic lupus erythematous (SLE). With lupus, the body's immune system targets its own body tissues. Lupus nephritis happens when lupus involves the kidneys. An immunosuppressive medication, such as cyclophosphamide or mycophenolate mofetil, is typically used with prednisone. A preliminary analysis of the safety data did not reveal any new or unexpected safety signals in patients receiving Rituxan

  • Lupus nephritis

    Nine patients died, of whom four had serious infections or septicaemia, and three developed end-stage renal failure (ESRF). The patient survival rate at 3 years and at last follow-up visit was 88% and 83.3%, respectively, whereas the renal survival rates (without ESRF) were 92% and 94.4% respectively. Cox regression analysis showed no relation of gender, age of onset, presence of hypertension, haematuria and proteinuria, estimated glomerular filtration rate, renal histology and response to therapy to the outcome of death or ESRF.

  • Lupus nephritis

    Lupus nephritis is treated with medications that suppress the immune system, so it stops attacking and damaging the kidneys. Standard treatment includes a corticosteroid, usually prednisone, to reduce inflammation in the kidneys.These medications—when taken as prescribed by a health care provider—further decrease the activity of the immune system and block the body’s immune cells from attacking the kidneys directly or making antibodies that attack the kidneys.

  • Lupus nephritis

    Genentech, Inc. (NYSE: DNA) and Biogen Idec (Nasdaq: BIIB) announced that a Phase III study of Rituxan® (rituximab) plus mycophenolate mofetil (MMF) and corticosteroids in patients with lupus nephritis did not meet its primary endpoint of significantly reducing disease activity at 52 weeks. The primary endpoint evaluated improvements in kidney response as measured by standard laboratory tests used to assess kidney health. 

Expert PPTs

Speaker PPTs

 

High Impact List of Articles

Conference Proceedings